Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen- independent PC-3 prostate cancer cells both in vitro and in vivo

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1655-1663

  Miyake, Hideaki ^a   Chi, Kim N ^a   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MITOXANTRONE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DETERMINATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSLATION INITIATION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; CLUSTERIN; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOXANTRONE; MOLECULAR CHAPERONES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; RNA, MESSENGER; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0034112089     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Denis, L., and Murphy, G. P. Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila.), 72; 3888-3895, 1993.
2. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998.
3. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1992.
4. Wagner, R. W. The state of the art in antisense research. Nat. Med., 1: 1116-1118, 1995.
5. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat. Med., 2: 668-675, 1996.
6. Cucco, C., and Calabretta, B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdrl antisense oligodeoxynucleotides. Cancer Res., 56: 4332-4337, 1996.
7. Ziegler, A., Luedke, G. H., Fabbro, D., Altman, K. H., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst., 89: 1027-1036, 1997.
8. Miyake, H., Tolcher, A., and Gleave, M. E. Antisense Bcl-2 oligode-oxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
9. Geiger, T., Muller, M., Monia, B. P., and Fabbro, D. Antitumor activity of a c-raf antisense oligodeoxynucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin. Cancer Res., 3: 1179-1185, 1997.
10. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elisas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
11. Campbell, M. J., Dawson, M., and Koeffler, H. P. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligodeoxynucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br. J. Cancer, 77: 739-744, 1998.
12. Miyake, H., Tolcher, A., and Gleave, M. E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst., 92: 34-41, 2000.
13. Blaschuk, O., Burdzy, K., and Fritz, I. B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem., 258: 7714-7720, 1983.
14. Rosenberg, M. E., and Silkensen, J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell. Biol., 27: 633-645, 1995.
15. Connor, J., Buttyan, R., Olsson, C. A., D'Agati, V., O'Toole, K., and Sawczuk, I. S. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int., 39: 1098-1103, 1991.
16. May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., and Finch, C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron, 5: 831-839, 1990.
17. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res., 51: 162-166, 1991.
18. Wunsche, W., Tenniswood, M. P., Schneider, M. R., and Vollmer, G. Estrogenic regulation of clusterin mRNA in normal and malignant endometrial tissue. Int. J. Cancer, 76: 684-688, 1998.
19. Schwochau, G. B., Nath, K. A., and Rosenberg, M. E. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int., 53: 1647-1653, 1998.
20. French, L. E., Sappino, A. P., Tschopp, J., and Schifferli, J. A. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J. Clin. Investig., 90: 1919-1925, 1992.
21. French, L. E., Wohlwend, A., Sappio, A. P., Tschopp, J., and Schifferli, J. A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Investig., 93: 877-884, 1994.
22. Montpetit, M. L., Lawless, K. R., and Tenniswood, M. Androgen-repressed messages in the rat ventral prostate. Prostate, 8: 25-36, 1986.
23. Sensibar, J. A., Griswold, M. D., Sylvester, S. R., Buttyan, R., Bardin, C. W., Cheng, C. Y., Dudek, S., and Lee, C. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology, 128: 2091-2102, 1991.
24. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
25. Wright, P. S., Cross-Doersen, D., Th'ng, J. P., Guo, X. W., Crissman, H. A., Bradbury, E. M., Montgomery, L. R., Thompson, F. Y., Loudy, D. E., Johnston, J. O., and Bitonti, A. J. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res., 222: 54-60, 1996.
26. Brandstrom, A., Westin, P., Bergh, A., Cajander, S., and Damber, J. E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res., 54: 3594-3601, 1994.
27. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res., 55: 2431-2437, 1995.
28. Steinberg, J., Oyasu, R., Lang, S., Sintich, S., Rademaker, A., Lee, C., Kozlowski, J. M., and Sensibar, J. A. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res., 3: 1701-1711, 1997.
29. Ho, S. M., Leav, I., Ghatak, S., Merk, F., Jagannathan, V. S., and Mallery, K. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am. J. Pathol., 153: 131-139, 1998.
30. Sintich, S. M., Steinberg, J., Kozlowski, J. M., Lee, C., Pruden, S., Sayeed, S., and Sensibar, J. A. Cytotoxic sensitivity to tumor necrosis factor-α in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate, 39: 87-93, 1999.
31. Miyake, H., Nelson, C., Rennie, P. S., and Gleave, M. E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res., 60: 170-176, 2000.
32. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S., Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S., and Saya, H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933-943, 1998.
33. Gleave, M., Hsieh, J. T., Gao, C. A., von Eschenbach, A. C., and Chung, L. W. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
34. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
35. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.
36. Bruchovsky, N., Snoek, R., Rennie, P., Akakura, K., Goldenberg, S. L., and Gleave, M. E. Control of tumor progression by maintenance of apoptosis. Prostate. 6: 13-21, 1996.
37. Gleave, M., Tolcher, A., Miyake, H., Nelson, C., Brown, B., Beraldi, E., and Goldi, J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res., 5: 2891-2898, 1999.
38. Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R., Gomella, L., Stern, C., and McAleer, C. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol., 22: 41-45, 1995.
39. Tannock, I. F., Osoba, D., Stockier, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756-1762, 1996.
40. Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., and Vogelzang, N. J. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol.. 17: 2506-2513, 1999.